Search
Ligand Pharmaceuticals Inc
LGNDAdd to Watchlist
297.150USD
-3.380-1.12%
Close 07-27 16:00（ET）Quotes delayed by 15 min
5.95BMarket Cap
38.72P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-24The current earnings forecast score of Ligand Pharmaceuticals Inc is 8.75, ranking 9 out of 155 in the Pharmaceuticals industry. The average price target is 232.50, with a high of 275.00 and a low of 220.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
323.300
Target Price
+7.58%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Ligand Pharmaceuticals Inc
LGND
9
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Ligand Pharmaceuticals Inc's expected revenue for the next quarter?
Ligand Pharmaceuticals Inc's expected revenue is 61.28M.
What is Ligand Pharmaceuticals Inc's price target?
Analysts forecast that Ligand Pharmaceuticals Inc's price target is USD 232.50, with the highest forecast at USD 275.00 and the lowest forecast at USD 220.00.
How have Ligand Pharmaceuticals IncLGND's recent earnings per share performed?
The market expectation was USD -0.67, while Ligand Pharmaceuticals IncLGND's earnings per share (EPS) for the previous quarter was USD 2.21. EPS for the next quarter is expected at USD 1.87.
What is the analyst rating for Ligand Pharmaceuticals Inc?
Based on the ratings of Ligand Pharmaceuticals Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.